DXCM vs ABT Stock Comparison

Dexcom and Abbott Laboratories Prices as of Nov 13, 2026 Peers: Industry group
DXCM Dexcom Inc
$83.33 -0.2% 1M +39.5% 1Y
Market cap
$30.83B
P/E
31.1x
Revenue (TTM)
$5.10B
Div. yield
–
Medical Devices Healthcare
7 wins
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$188.27B
P/E
40.0x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
4 wins

Head to Head

11 decided of 12

Dexcom leads on 7 of the 12 questions below (Dexcom 7, Abbott Laboratories 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDXCMABTLeader
Larger companyMarket capitalisation $30.83B $188.27B ABT
Cheaper on earningsLower P/E, profitable companies only 31.1x 40.0x DXCM
Cheaper on forward earningsLower price / next fiscal year consensus EPS 29.1x 19.1x ABT
Faster revenue growthRevenue growth, trailing twelve months +13.0% +10.0% DXCM
More profitableNet margin, trailing twelve months 19.4% 9.7% DXCM
Better return on capitalReturn on invested capital 32.4% 5.7% DXCM
Less leveragedLower net debt / EBITDA -0.9x 2.5x DXCM
Higher dividend yieldTrailing dividend yield 0.00% 0.02% –
Better 1-year returnPrice return, last 12 months +39.5% -16.0% DXCM
Better 5-year returnAnnualised price return, 5 years -12.4%/yr -3.3%/yr ABT
Less volatileAnnualised volatility, 1 year 37.9% 28.5% ABT
Higher overall scoreMean of the five percentile scores vs peers 80/100 56/100 DXCM

Percentile Scorecard

DXCMABT

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDXCMABT
Valuation 67 #82 of 243 74 #65 of 243
Growth 83 #40 of 228 26 #168 of 228
Profitability 100 #1 of 222 82 #41 of 222
Financial Health 59 #103 of 248 33 #167 of 248
Shareholder Returns 91 #15 of 158 65 #56 of 158
Overall 80 56
  • DXCM ranked among 252 companies in Medical Devices and Diagnostics
  • ABT ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDXCMABTSPY
1 month -0.2%+5.4% -2.0%
3 months -7.2%-2.4% -2.8%
6 months +35.2%+28.5% +2.0%
Year to date +25.6%-13.4% +10.6%
1 year +39.5%-16.0% +12.2%
3 years -17.8%+11.8% +68.1%
3 years, per year -6.3%+3.8% +18.9%
5 years -48.4%-15.5% +61.4%
5 years, per year -12.4%-3.3% +10.1%
10 years +411.2%+170.4% +248.5%
10 years, per year +17.7%+10.5% +13.3%

Risk

MeasureDXCMABTSPY
Volatility, 1Y 37.9%28.5% 13.6%
Downside volatility, 1Y 34.3%27.8% 13.9%
Beta vs S&P 500, 1Y 0.720.07 1.00
Return / volatility, 1Y 1.04-0.56 0.90
Max drawdown, 5Y -66.3%-41.6% -25.4%
From 52-week high -9.8%-16.9% -3.2%
52-week high $92.34$130.59 $779.14
52-week low $57.56$82.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDXCMABT
P/E now vs peer median 31.5xmedian 26.5x 40.0xmedian 26.5x
P/S now vs peer median 6.1xmedian 2.7x 3.9xmedian 2.7x
EV/EBITDA now vs peer median 19.7xmedian 18.4x 20.3xmedian 18.4x
P/FCF now vs peer median 28.3xmedian 25.4x 27.8xmedian 25.4x
P/B now vs peer median 12.3xmedian 2.5x 3.6xmedian 2.5x
PEG now vs peer median 0.73median 0.98 -13.92median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDXCMABT
Revenue $5.10B $48.23B
Gross profit $3.24B $27.46B
Operating income $1.22B $6.65B
Net income $991.00M $4.70B
Free cash flow $1.10B $6.76B
R&D $608.10M $3.31B
EPS (diluted) $2.58 $2.70
Cash & equivalents $961.40M $4.05B
Total debt $389.80M $31.16B
Shares (diluted) 383.50M 1.74B
Enterprise value $22.65B $162.14B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDXCMABT
P/E 31.5x 40.0x
P/FCF 28.3x 27.8x
P/Operating cash flow 22.0x 21.2x
P/S 6.1x 3.9x
P/B 12.3x 3.6x
P/Tangible book 12.7x 5.9x
EV/EBITDA 19.7x 20.3x
EV/EBIT 24.2x 32.3x
EV/Revenue 5.8x 4.5x
EV/FCF 27.0x 31.8x
EV/Operating cash flow 21.0x 24.3x
PEG (3Y EPS CAGR) 0.73 -13.92

Growth

14 metrics
MetricDXCMABT
Revenue growth (1Y) 13.0% 10.0%
Revenue CAGR (3Y) 14.5% 6.5%
Gross profit growth (1Y) 21.5% 12.1%
Gross profit CAGR (3Y) 14.2% 7.8%
Operating income growth (1Y) 57.4% -13.8%
Operating income CAGR (3Y) 34.2% 3.5%
Net income growth (1Y) 37.5% -66.4%
Net income CAGR (3Y) 38.0% -3.1%
EPS growth (1Y) 46.1% -66.1%
EPS CAGR (3Y) 43.0% -2.9%
Operating cash flow growth (1Y) -2.3% -2.9%
Operating cash flow CAGR (3Y) 23.7% 10.6%
Free cash flow growth (1Y) 3.4% -2.3%
Free cash flow CAGR (3Y) 30.0% 14.6%

Profitability

14 metrics
MetricDXCMABT
Gross margin 63.4% 56.9%
EBITDA margin 29.5% 21.9%
Operating margin 24.0% 13.8%
Pretax margin 24.7% 13.6%
Net margin 19.4% 9.7%
FCF margin 21.5% 14.0%
Operating cash flow margin 27.7% 18.4%
Return on equity 38.4% 9.1%
Return on assets 15.6% 4.3%
Return on invested capital 32.4% 5.7%
Return on capital employed 29.9% 7.2%
Asset turnover 0.8x 0.4x
Cash conversion (OCF / net income) 1.4x 1.9x
Stock comp / revenue 3.0% 1.5%

Financial Health

11 metrics
MetricDXCMABT
Debt / assets 6.2% 28.8%
Debt / equity 0.2x 0.6x
Net debt / EBITDA -0.9x 2.5x
Debt / FCF 0.4x 4.6x
Liabilities / assets 59.4% 52.3%
Equity / assets 40.6% 47.7%
Interest coverage – 6.7x
Current ratio 1.7x 1.5x
Quick ratio 1.3x 0.8x
Cash ratio 0.8x 0.3x
Altman Z-score 7.53 3.36

Shareholder Returns

7 metrics
MetricDXCMABT
Dividend yield – 2.3%
Net buyback yield 2.2% 0.7%
Shareholder yield 2.2% 3.0%
Payout ratio (earnings) – 92.0%
Payout ratio (FCF) – 64.0%
Dividend growth (1Y) – 6.9%
Dividend CAGR (3Y) – 7.4%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDXCMABT
Forward P/E 29.1xFY2026 19.1xFY2026
EPS, next fiscal year $2.86FY2026 $5.69FY2026
EPS growth, next FY +36.8%FY2026 +10.5%FY2026
EPS growth, the year after +4.2% +10.2%
Revenue, next fiscal year $5.08BFY2026 $52.99BFY2026
Revenue growth, next FY +9.0%FY2026 +19.5%FY2026
Revenue growth, the year after +16.0% -2.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDXCMABT
Held by institutions 100.0% 79.2%
Institutions holding 977 2,983
Change in shares held, QoQ +6.3% +0.3%
Institutions buying 521 1,261
Institutions selling 345 1,379
Buyers to sellers 1.51 0.91

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DXCMABT
DXCM 1.00 0.36
ABT 0.36 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DXCM and ABT?

Abbott Laboratories (ABT) is the largest by market capitalisation: Dexcom (DXCM) $30.83B, Abbott Laboratories (ABT) $188.27B.

Which stock is cheaper, DXCM and ABT?

Dexcom (DXCM) trades on the lowest price-to-earnings ratio (Dexcom (DXCM) 31.1x, Abbott Laboratories (ABT) 40.0x). On next year's consensus earnings, Abbott Laboratories (ABT) is cheapest (Dexcom (DXCM) 29.1x, Abbott Laboratories (ABT) 19.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Dexcom (DXCM) grew revenue fastest over the trailing twelve months: Dexcom (DXCM) +13.0%, Abbott Laboratories (ABT) +10.0%.

Which company is more profitable?

Dexcom (DXCM) has the highest net margin (Dexcom (DXCM) 19.4%, Abbott Laboratories (ABT) 9.7%). On return on invested capital, Dexcom (DXCM) leads (Dexcom (DXCM) 32.4%, Abbott Laboratories (ABT) 5.7%).

Which stock has performed better?

Over the past year Dexcom (DXCM) returned the most: Dexcom (DXCM) +39.5%, Abbott Laboratories (ABT) -16.0%. Over five years, Abbott Laboratories (ABT) compounded fastest (Dexcom (DXCM) -12.4%/yr, Abbott Laboratories (ABT) -3.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Dexcom (DXCM) 0.00%, Abbott Laboratories (ABT) 0.02%. Dexcom (DXCM) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Abbott Laboratories (ABT) has been the steadiest (Dexcom (DXCM) 37.9%, Abbott Laboratories (ABT) 28.5%). Volatility measures how widely the price swings, not the risk of the business.

Do DXCM and ABT move together?

Their daily returns over the past year have a correlation of 0.36, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, DXCM and ABT?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Dexcom (DXCM) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.